Expression of Concern

Alzahrani, Rayan A; Alghamdi, Ameera F; Alzahrani, Mohammed Ali; Alghamdi, Majed; Alghamdi, Malak F; Alzahrani, Amjad A; Alghamdi, Abdullah M.; Alzahrani, Manal K; Alghamdi, Talal S; Alghamdi, Rahaf S; Alqarni, Fahad A; Al-Zahrani, Ahmed H; Al-Hawaj, Faisal

doi:10.7759/cureus.x19

Cited by 2 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is conceivable, based on the currently acknowledged structural and functional differences, to divide the SLC15 family of peptide transporters into two subfamilies [11]. , His-Leu-lopinavir [491], alafosfalin [536], cephalexin [18,143,238,245,476,713,714], valganciclovir [681,741], mirogabalin [817], -Ala-Lys-AMCA [4,13,369,423] muramyl dipeptide [342,683], D-Ala-Lys-AMCA [423,691,783], -iE-DAP [683,689],…”

Section: Overviewmentioning

confidence: 99%

“…-Ala-Lys-AMCA [4,12,13,169,423,614,623,683,694,856,857], alafosfalin [536], Javamide-I(N-coumaroyltryptophan)/-II(N-caffeoyltryptophan) esters (javamide-I-O-methyl ester and javamide-II-O-methyl ester), acetylated prolyl-glycyl-proline (Ac-PGP; the acetylated form of the collagen-derived matrikine PGP) [610], mirogabalin [817] Endogenous substrates 5-aminolevulinic acid […”

Section: Slc15 Family Of Peptide Transporters S410mentioning

confidence: 99%

“…Two families (SLC3 and SLC7) only generate functional transporters as heteromeric partners, where one partner is a single TM domain protein. Membrane topology predictions for other families suggest 3,4,6,7,8,9,10,11,12,13 or 14 TM domains. The SLC transporters include members which function as antiports, where solute movement in one direction is balanced by a solute moving in the reverse direction.…”

mentioning

confidence: 99%

See 2 more Smart Citations

The Concise Guide to PHARMACOLOGY 2023/24: Transporters

Alexander,

Fabbro,

Kelly

et al. 2023

British J Pharmacology

View full text Add to dashboard Cite

The Concise Guide to PHARMACOLOGY 2023/24 is the sixth in this series of biennial publications. The Concise Guide provides concise overviews, mostly in tabular format, of the key properties of approximately 1800 drug targets, and over 6000 interactions with about 3900 ligands. There is an emphasis on selective pharmacology (where available), plus links to the open access knowledgebase source of drug targets and their ligands (https://www.guidetopharmacology.org/), which provides more detailed views of target and ligand properties. Although the Concise Guide constitutes almost 500 pages, the material presented is substantially reduced compared to information and links presented on the website. It provides a permanent, citable, point‐in‐time record that will survive database updates. The full contents of this section can be found at http://onlinelibrary.wiley.com/doi/10.1111/bph.16182. Transporters are one of the six major pharmacological targets into which the Guide is divided, with the others being: G protein‐coupled receptors, ion channels, nuclear hormone receptors, catalytic receptors and enzymes. These are presented with nomenclature guidance and summary information on the best available pharmacological tools, alongside key references and suggestions for further reading. The landscape format of the Concise Guide is designed to facilitate comparison of related targets from material contemporary to mid‐2023, and supersedes data presented in the 2021/22, 2019/20, 2017/18, 2015/16 and 2013/14 Concise Guides and previous Guides to Receptors and Channels. It is produced in close conjunction with the Nomenclature and Standards Committee of the International Union of Basic and Clinical Pharmacology (NC‐IUPHAR), therefore, providing official IUPHAR classification and nomenclature for human drug targets, where appropriate.

show abstract

Section: Overviewmentioning

confidence: 99%

Section: Slc15 Family Of Peptide Transporters S410mentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

The Concise Guide to PHARMACOLOGY 2023/24: Transporters

Alexander,

Fabbro,

Kelly

et al. 2023

British J Pharmacology

View full text Add to dashboard Cite

show abstract

“…Metal–organic frameworks (MOFs) are a group of nanomaterials with highly porous crystalline structures composed of metal ions coordinated with organic ligands. [ 3–5 ] MOFs possess an incredibly high surface area, which allows for efficient adsorption and encapsulation of bioactive molecules, drugs, and growth factors. They also have interesting properties such as a high level of active site, low skeleton density, ideal mechanical, chemical, and thermal stability, high porosity with adjustable uniform size, and ease of functionalization, which make them superior to other materials.…”

Section: Introductionmentioning

confidence: 99%

MOFs and MOF‐Based Composites as Next‐Generation Materials for Wound Healing and Dressings

Bigham,

Islami,

Khosravi

et al. 2024

Small

View full text Add to dashboard Cite

In recent years, there has been growing interest in developing innovative materials and therapeutic strategies to enhance wound healing outcomes, especially for chronic wounds and antimicrobial resistance. Metal–organic frameworks (MOFs) represent a promising class of materials for next‐generation wound healing and dressings. Their high surface area, pore structures, stimuli‐responsiveness, antibacterial properties, biocompatibility, and potential for combination therapies make them suitable for complex wound care challenges. MOF‐based composites promote cell proliferation, angiogenesis, and matrix synthesis, acting as carriers for bioactive molecules and promoting tissue regeneration. They also have stimuli‐responsivity, enabling photothermal therapies for skin cancer and infections. Herein, a critical analysis of the current state of research on MOFs and MOF‐based composites for wound healing and dressings is provided, offering valuable insights into the potential applications, challenges, and future directions in this field. This literature review has targeted the multifunctionality nature of MOFs in wound‐disease therapy and healing from different aspects and discussed the most recent advancements made in the field. In this context, the potential reader will find how the MOFs contributed to this field to yield more effective, functional, and innovative dressings and how they lead to the next generation of biomaterials for skin therapy and regeneration.

show abstract

Expression of Concern

Cited by 2 publications

References 0 publications

The Concise Guide to PHARMACOLOGY 2023/24: Transporters

The Concise Guide to PHARMACOLOGY 2023/24: Transporters

MOFs and MOF‐Based Composites as Next‐Generation Materials for Wound Healing and Dressings

Contact Info

Product

Resources

About